#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

Acceptability of and treatment preferences for recurrent bacterial vaginosis—Topical lactic acid gel or oral metronidazole antibiotic: Qualitative findings from the VITA trial


Autoři: Jocelyn Anstey Watkins aff001;  Jonathan D. C. Ross aff002;  Sukhwinder Thandi aff003;  Clare Brittain aff003;  Joe Kai aff004;  Frances Griffiths aff001
Působiště autorů: Warwick Medical School, University of Warwick, Coventry, England, United Kingdom aff001;  University Hospitals Birmingham NHS Foundation Trust, Birmingham, England, United Kingdom aff002;  Nottingham Clinical Trials Unit, University of Nottingham, Nottingham, England, United Kingdom aff003;  Division of Primary Care, University of Nottingham, Nottingham, England, United Kingdom aff004;  Centre for Health Policy, University of the Witwatersrand, Johannesburg, South Africa aff005
Vyšlo v časopise: PLoS ONE 14(11)
Kategorie: Research Article
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.pone.0224964

Souhrn

Background

Bacterial vaginosis (BV) is associated with an elevated vaginal pH and the presence of abnormal offensive discharge. It is common, often recurrent, and the most effective treatment regimen is unknown. ‘Metronidazole Versus lactic acId for Treating bacterial vAginosis’ (VITA) is a UK-based randomised controlled trial assessing clinical and cost-effectiveness of topical lactic acid gel compared to oral metronidazole antibiotic for treating second and subsequent BV episodes. Few BV trials report on women’s preferences for treatment in the context of their own experiences.

Method

This qualitative study investigated the acceptability and tolerability of the two treatments. During the trial, semi-structured telephone interviews were undertaken between January—May 2018. A total of 33 women diagnosed with BV were consecutively sampled then interviewed from six sites across England. Thematic analysis was guided by the acceptability of health interventions framework. Potential causes of BV and its impact on women’s lives were explored in addition to women’s treatment preference and perceived treatment effectiveness.

Results

Although women felt antibiotics treat BV effectively, and were associated with longer time periods between episodes, they generally preferred using the lactic acid gel because of ease of use, once daily application and less side-effects. Women would recommend the lactic acid gel to others for mild cases of BV but to take antibiotics when more severe. The risk of antibiotic drug resistance was a common concern. Self-help medicating or self-decision to not treat was also evident due to prior experience of poor outcomes from treatment. Triggers of BV were attributed to personal hygiene habits–soaps used to wash the vagina and sexual practices such as unprotected sex.

Conclusion

Acceptability and preference for topical lactic acid gel or oral metronidazole tablets in the treatment of recurrent BV was affected by personal choice relating to affective attitude, burden, ethicality, intervention coherence, opportunity costs, and self-efficacy. These differed depending on ease of use, tolerability and past experiences, but not necessarily based on perceived drug effectiveness. Knowledge of a patient preference for topical lactic acid gel therapy despite lower perceived effectiveness may be useful for clinicians when making treatment decisions.

Klíčová slova:

Drug therapy – Antibiotics – Jaw – Behavior – Antibiotic resistance – Lactic acid – Bacterial vaginosis


Zdroje

1. Bradshaw CS, Brotman RM. Making inroads into improving treatment of bacterial vaginosis–striving for long-term cure. BMC infectious diseases. 2015;15(1):292.

2. Forsum U, Holst E, Larsson P-G, Vasquez A, Jakobsson T, Mattsby‐Baltzer I. Bacterial vaginosis–a microbiological and immunological enigma. Apmis. 2005;113(2):81–90. doi: 10.1111/j.1600-0463.2005.apm1130201.x 15723682

3. Turovskiy Y, Noll KS, Chikindas ML. The aetiology of bacterial vaginosis. Journal of applied microbiology. 2011;110(5):1105–28. doi: 10.1111/j.1365-2672.2011.04977.x 21332897

4. Wilson J. Managing recurrent bacterial vaginosis. Sexually transmitted infections. 2004;80(1):8–11. doi: 10.1136/sti.2002.002733 14755028

5. Hull CE, McLellan AR. Acute and Recurrent Bacterial Vaginosis. Clinician Reviews. 2016;44.

6. O'brien RF. Bacterial vaginosis: many questions-any answers? Current opinion in pediatrics. 2005;17(4):473–9. doi: 10.1097/01.mop.0000170516.35272.45 16012258

7. Machado D, Castro J, Palmeira-de-Oliveira A, Martinez-de-Oliveira J, Cerca N. Bacterial Vaginosis Biofilms: Challenges to Current Therapies and Emerging Solutions. 2016.

8. Phillip Hay SP, David Daniels. UK National Guideline for the management of Bacterial Vaginosis 2012. UK: Clinical Effectiveness Group British Association for Sexual Health and HIV; 2012.

9. Ma L, Su J, Su Y, Sun W, Zeng Z. Probiotics administered intravaginally as a complementary therapy combined with antibiotics for the treatment of bacterial vaginosis: a systematic review protocol. BMJ open. 2017;7(10):e019301. doi: 10.1136/bmjopen-2017-019301 29038188

10. Hemmerling A, Harrison W, Schroeder A, Park J, Korn A, Shiboski S, et al. Phase 2a study assessing colonization efficiency, safety, and acceptability of Lactobacillus crispatus CTV-05 in women with bacterial vaginosis. Sexually transmitted diseases. 2010;37(12):745–50. doi: 10.1097/OLQ.0b013e3181e50026 20644497

11. Mogha KV, Prajapati JB. Evaluation of probiotic cream by in-vitro tests for treatment of bacterial vaginosis conditions. Reviews in Medical Microbiology. 2017;28(1):19–25.

12. NICE. UK National Guideline for the management of Bacterial Vaginosis 2012: National Institue for Health and Care Excellence 2012 [Available from: https://www.evidence.nhs.uk/search?q=bacterial+vaginosis.

13. Armitage C. Management of Vaginal Discharge. Women's Health in Primary Care. 2017:37.

14. Devaux S, Castela A, Archier E, Gallini A, Joly P, Misery L, et al. Adherence to topical treatment in psoriasis: a systematic literature review. Journal of the European Academy of Dermatology and Venereology. 2012;26:61–7. doi: 10.1111/j.1468-3083.2012.04525.x 22512682

15. Kazdin AE. Acceptability of alternative treatments for deviant child behavior. Journal of Applied Behavior Analysis. 1980;13(2):259–73. doi: 10.1901/jaba.1980.13-259 7380752

16. Miltenberger RG. Assessment of treatment acceptability: A review of the literature. Topics in Early Childhood Special Education. 1990;10(3):24–38.

17. Barbosa CD, Balp M-M, Kulich K, Germain N, Rofail D. A literature review to explore the link between treatment satisfaction and adherence, compliance, and persistence. Patient preference and adherence. 2012;6:39. doi: 10.2147/PPA.S24752 22272068

18. Sekhon M, Cartwright M, Francis JJ. Acceptability of healthcare interventions: an overview of reviews and development of a theoretical framework. BMC health services research. 2017;17(1):88. doi: 10.1186/s12913-017-2031-8 28126032

19. Bilardi JE, Walker S, Temple-Smith M, McNair R, Mooney-Somers J, Bellhouse C, et al. The burden of bacterial vaginosis: women’s experience of the physical, emotional, sexual and social impact of living with recurrent bacterial vaginosis. PloS one. 2013;8(9):e74378. doi: 10.1371/journal.pone.0074378 24040236

20. ISRCTN. Metronidazole versus lactic acId for treating bacterial vaginosis ISRCTN14161293 registry BMC Springer Nature 2019 [Available from: https://doi.org/10.1186/ISRCTN14161293.

21. Lindsay Armstrong-Buisseret CB, David Miruna, Dean Gillian, Griffiths Frances, Hepburn Trish, Jackson Louise, Kai Joe, Montgomery Alan, Roberts Tracy, Thandi Sukhwinder and Ross Jonathan D. C. Protocol has been submitted—Metronidazole versus lactic acid for treating bacterial vaginosis (VITA): protocol for a randomised controlled trial to assess the clinical and cost effectiveness of topical lactic acid gel for treating second and subsequent episodes of bacterial vaginosis. Trials. 2019;in submission

22. O’Brien BC, Harris IB, Beckman TJ, Reed DA, Cook DA. Standards for reporting qualitative research: a synthesis of recommendations. Academic Medicine. 2014;89(9):1245–51. doi: 10.1097/ACM.0000000000000388 24979285

23. Braun V, Clarke V. Using thematic analysis in psychology. Qualitative Research in Psychology. 2006;3(2):77–101.

24. Bilardi JE, Walker SM, Temple-Smith MJ, McNair RP, Mooney-Somers J, Vodstrcil LA, et al. Women view key sexual behaviours as the trigger for the onset and recurrence of bacterial vaginosis. PloS one. 2017;12(3):e0173637. doi: 10.1371/journal.pone.0173637 28278277

25. Adolfsson A, Hagander A, Mahjoubipour F, Larsson P-G. How Vaginal Infections Impact Women's Everyday Life: Women's Lived Experiences of Bacterial Vaginosis and Recurrent Vulvovaginal Candidiasis. Advances in Sexual Medicine. 2017;7(1):1–19.

26. Payne SC, Cromer PR, Stanek MK, Palmer AA. Evidence of African‐American women's frustrations with chronic recurrent bacterial vaginosis. Journal of the American Academy of Nurse Practitioners. 2010;22(2):101–8. doi: 10.1111/j.1745-7599.2009.00474.x 20132368

27. McGowan I, Gomez K, Bruder K, Febo I, Chen BA, Richardson BA, et al. Phase 1 randomized trial of the vaginal safety and acceptability of SPL7013 gel (VivaGel®) in sexually active young women (MTN-004). AIDS (London, England). 2011;25(8):1057.

28. Coggins C, Blanchard K, Alvarez F, Brache V, Weisberg E, Kilmarx P, et al. Preliminary safety and acceptability of a carrageenan gel for possible use as a vaginal microbicide. Sexually Transmitted Infections. 2000;76(6):480–3. doi: 10.1136/sti.76.6.480 11221133


Článok vyšiel v časopise

PLOS One


2019 Číslo 11
Najčítanejšie tento týždeň
Najčítanejšie v tomto čísle
Kurzy

Zvýšte si kvalifikáciu online z pohodlia domova

Aktuální možnosti diagnostiky a léčby litiáz
nový kurz
Autori: MUDr. Tomáš Ürge, PhD.

Všetky kurzy
Prihlásenie
Zabudnuté heslo

Zadajte e-mailovú adresu, s ktorou ste vytvárali účet. Budú Vám na ňu zasielané informácie k nastaveniu nového hesla.

Prihlásenie

Nemáte účet?  Registrujte sa

#ADS_BOTTOM_SCRIPTS#